Hologic now has a fresh CEO and two added board members, thanks to the machinations of activist investor Carl Icahn. But the new leader of the Massachusetts company known for women-focused diagnostic medical imaging and surgical products insists growth is a much bigger priority over a sale, at least for now.
Researchers have come up with an affordable, quick and accurate way to diagnose brain cancer in a fraction of the time that current technology allows. The early results are promising enough that they've patented their new approach.
Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.
Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.
Considering the number of milestones Oxford Immunotec Global has already achieved, the maker of a next-generation tuberculosis diagnostic test could very easily hit the high end of its targeted $13-$15 IPO price range.
A month after filing IPO plans, molecular diagnostics test maker Veracyte finally went public on Oct. 30. The South San Francisco company said it sold 5 million shares of common stock for $13 each and pulled in $65 million.
A massive research partnership focused on advancing genomic medicine and diagnostics in Latin America will be kicking into a new phase of work, backed by $74 million in additional funding from a foundation established by Mexican billionaire Carlos Slim. The Broad Institute of Harvard and MIT is housing the effort.
Scientists at Sweden's Uppsala University have used PET scanning and an injected tracer to visualize and track the progression of pain in a soft tissue injury. By doing so, they hope to better diagnose the mechanisms behind a given problem and come up with better treatments.
The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
U.K. researchers believe they've come up with a rapid blood test that could detect sepsis at a patient's bedside, enabling quicker treatment of the severe and sometimes fatal infection.